We critically evaluate the controversies on the efficacy of PPAR agonists, highlight cross talk with HIF-1<i>α</i>/NF-<i>κ</i>B/Nrf2, and propose a phenotype-based stratification for sepsis therapy, a perspective that has not been explored in the literature. This evidence concerns the gene PPARA and Sepsis.